
    
      Primary Objective of Phase I

        -  To determine the maximal and Phase II dose of inhaled doxorubicin HCl when given in
           combination with IV docetaxel and cisplatin in patients with locally advanced or
           metastatic unresectable NSCLC who have not been previously treated with chemotherapy.

      Primary Objective of Phase II

        -  To obtain preliminary evidence of therapeutic activity using imaging studies in patients
           with measurable or evaluable lung lesions and serial measurements of disease-related
           pulmonary symptoms and pulmonary function.

      Secondary Objective

        -  To define the nature of the toxic effects of inhaled doxorubicin when given in
           combination with IV docetaxel and cisplatin.
    
  